Oxford, UK, November 22, 2022 (Yahoo) -- Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023.
Read full article here.
South San Francisco, CA, March 14. 2023 (Business Wire) -- Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced i
San Diego, CA, March 14, 2023 (Globe Newswire) -- Medical Marijuana, Inc., a holding company with operating assets dedicated to the cannabis and hemp industries, along with portfolio investments in co
Cambridge, MA, March 6, 2023 (Business Wire) -- Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable anti-tumor response, today
